{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 89 of 122', 'Used or unused investigational product may be destroyed at the study site according to', 'standard institutional procedures if the sponsor agrees with the procedure, and after', 'investigational product accountability has been conducted by the sponsor or representative,', 'unless otherwise approved. A copy of the standard institutional procedure for destroying', 'investigational products will be provided to the sponsor or designee upon request for review', 'and approval before the first onsite destruction. Unused investigational product not', 'destroyed at the site must be returned to the sponsor-designated facility at the end of the', 'study or upon expiration.', '13.4 Retention of Records', 'The investigator must make original study data (paper or electronic) accessible to the study', 'monitor, other authorized sponsor representatives, and regulatory agency inspectors upon', 'request. A file for each subject must be maintained that includes the signed informed consent', 'and assent forms and copies of all source documentation related to that subject. The', 'investigator must ensure the reliability and availability of source documents from which the', 'information on the case report form was derived.', 'Investigators must maintain all study documentation for at least 2 years following the', 'approval of the investigational product, or until 2 years after the investigational product', 'program is discontinued, or longer if required by local regulations. Study documentation', 'includes but is not limited to all essential documents as defined in ICH E6 Guidelines for', 'Good Clinical Practice. The sponsor or designee will notify the investigator when any', 'records may be discarded, but investigators must comply with local and national regulations.', '13.5 Protocol Deviations', 'The investigators and study site staff will conduct the study in accordance with the approved', 'protocol. Any intentional or unintentional change, divergence, or departure from the study', 'design or procedures will be considered a protocol deviation. Protocol deviations will be', 'documented in accordance with the study manual and may include electronic data capture or', 'other means.', 'Where necessary, the investigator may deviate from the protocol to eliminate an immediate', 'hazard to a study subject, although every effort should be made to discuss this with the', 'sponsor medical monitor in advance.', '13.6 Study Termination', 'The sponsor will terminate this study following completion of the study objectives, or earlier', 'if deemed necessary.', 'The sponsor reserves the right to terminate the study anytime and for any reason. When the', 'sponsor is aware of information on matters concerning the quality, efficacy, and safety of the', 'investigational products, as well as other important information that may affect proper', 'conduct of the clinical study, the sponsor may terminate the study and send a written notice']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 90 of 122', 'of the termination along with the reasons to the investigator and EC/regulatory authorities as', 'required.', \"If an investigator or the investigator's EC intends to terminate participation in the study, the\", 'investigator must immediately inform the sponsor and provide the reason for it.', '14 USE OF STUDY INFORMATION AND PUBLICATION', 'The results of this study will be published or presented at scientific meetings in a timely,', 'objective, and scientifically and clinically meaningful manner that is consistent with good', 'science and industry and regulatory authority guidance, while addressing the need to protect', 'the intellectual property of Aimmune (sponsor), regardless of the study outcome. The data', 'generated in this clinical study are Aimmune Confidential Information and the exclusive', \"property of the sponsor. The sponsor's written approval is required before disclosing any\", 'information related to this clinical study, and no investigator-initiated publications may be', 'published until all protocol-defined primary and secondary endpoints are published in a', 'manuscript. Every attempt will be made to minimize the interval between the completion of', 'data analysis and publication of the study results. The sponsor, in consultation with the', 'authors, will make the final decisions on the timing of presentation of study endpoint data', 'and the publication venues (congresses/journals).', 'Each investigator agrees to submit all manuscripts or congress abstracts and', 'posters/presentations to the sponsor prior to submission. This allows the sponsor to protect', 'proprietary information, provide comments based on information from other studies that may', 'not yet be available to the investigator, and ensure scientific and clinical accuracy. The', 'processes of producing and reviewing reports, manuscripts, and presentations based on the', \"data from this study will be detailed in the investigator's clinical study agreement.\", 'Any formal publication of the study in which input of sponsor personnel exceeded that of', 'conventional monitoring will be considered as a joint publication by the investigator and the', 'appropriate sponsor personnel. Authorship will be determined by mutual agreement and all', 'authors must meet the criteria for authorship established by the International Committee of', 'Medical Journal Editors (ICMJE) Uniform Requirements for Manuscripts or stricter local', 'criteria (ICMJE, 2015; updated ICMJE recommendations, 2016). The sponsor does not', 'compensate for authorship of a publication and all authors will be required to disclose, as part', 'of the publication submission, any potential conflicts of interest, including pertinent financial', 'or personal relationships with the sponsor or related entities, including sponsors of competing', 'products that might be perceived to be a source of bias. Authorship is decided on an', \"individual basis and the sponsor's publications committee and sponsor representatives will\", 'mutually determine authors and their sequence on individual publications based on the', 'relative contribution of each author to the study and/or publication.', 'Investigators in this study agree to have their name listed as an investigator in any', 'publication reporting results from this study, whether or not they are an author on the', 'publication.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 91 of 122', 'Professional medical writing support is permissible, and any writing support will be', 'acknowledged in each applicable publication, explaining the role the professional writer had', 'in the drafting of the publication.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 92 of 122', '15 REFERENCES', 'Allen KJ, Remington BC, Baumert JL, Crevel RW, Houben GF, Brooke-Taylor S, et al. Allergen reference', 'doses for precautionary labeling (VITAL 2.0): clinical implications. J Allergy Clin Immunol.', '2014;133(1):156-64.', 'Altschul AS, Scherrer DL, Mu\u00f1oz-Furlong A, Sicherer SH. Manufacturing and labeling issues for commercial', 'products: relevance to food allergy. J Allergy Clin Immunol. 2001;108(3):468.', 'Anagnostou K, Islam S, King Y, Foley L, Pasea L, Bond S, et al. Assessing the efficacy of oral immunotherapy', 'for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet.', '2014;383(9925):1297-304.', 'Avery NJ, King RM, Knight S, Hourihane JO. Assessment of quality of life in children with peanut allergy.', 'Pediatr Allergy Immunol. 2003;14(5):378-82.', 'Baumert JL, Taylor SL, Koppelman SJ. Quantitative assessment of the safety benefits associated with', 'increasing clinical peanut thresholds through immunotherapy. J Allergy Clin Immunol Pract. 2017. [Epub ahead', 'of print]', 'Beyer K. A European perspective on immunotherapy for food allergies. J Allergy Clin Immunol.', '2012;129(5):1179-84', 'Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of an abbreviated', 'Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive', 'medications. Health Qual Life Outcomes. 2009 Apr 27;7:36.', \"Bird JA, Spergel JM, Jones SM, Rachid RA, Assa'ad AH, Wang J, et al. The efficacy of AR101,\", 'a peanut-derived pharmaceutical for oral immunotherapy (OIT), is maintained and tolerability is increased with', 'low-dose maintenance therapy. J Allergy Clin Immunol. 2016;137(2 Suppl):AB408.', \"Bird JA, Spergel JM, Jones SM, Rachid RA, Assa'ad AH, Wang J, et al. Efficacy and safety of AR101 in oral\", 'immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2', 'clinical trial. J Allergy Clin Immunol Pract. 2018;6(2):476-85.e3.', 'Blumchen K, Ulbricht H, Staden U, Dobberstein K, Beschorner J, de Oliveira LC, et al. Oral peanut', 'immunotherapy in children with peanut anaphylaxis. J Allergy Clin Immunol. 2010;126(1):83-91.', 'Burks AW, Jones SM, Wood RA, Fleischer DM, Sicherer SH, Lindblad RW, et al. Oral immunotherapy for', 'treatment of egg allergy in children. N Engl J Med. 2012;367(3):233-43.', 'Cohen BL, Noone S, Mu\u00f1oz-Furlong A, Sicherer SH. Development of a questionnaire to measure quality of life', 'in families with a child with food allergy. J Allergy Clin Immunol. 2004;114(5):1159-63', 'Dellon ES. Approach to diagnosis of eosinophilic esophagitis. Gastroenterol Hepatol (N Y). 2011;7(11):742-4.', 'Dellon ES, Gonsalves N, Hirano I, Furuta GT, Liacouras CA, Katzka DA. ACG clinical guideline: Evidenced', 'based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis', '(EoE). Am J Gastroenterol. 2013;108(5):679-92.', 'Deschildre A, Elegb\u00e9d\u00e9 CF, Just J, Bruy\u00e8re O, Van der Brempt X, Papadopoulos A, et al. Peanut-allergic', \"patients in the MIRABEL survey: characteristics, allergists' dietary advice and lessons from real life.\", 'Clin Exp Allergy. 2016;46(4):610-20', 'Downie SR, Andersson M, Rimmer J, Leuppi JD, Xuan W, Akerlund A, et al. Symptoms of persistent allergic', 'rhinitis during a full calendar year in house dust mite-sensitive subjects. Allergy. 2004;59(4):406-14', 'DunnGalvin A, Cullinane C, Daly DA, Flokstra-de Blok BM, Dubois AE, Hourihane JO. Longitudinal validity', 'and responsiveness of the Food Allergy Quality of Life Questionnaire - Parent Form in children 0-12 years', 'following positive and negative food challenges. Clin Exp Allergy. 2010;40(3):476-85.', 'DunnGalvin A, de BlokFlokstra BM, Burks AW, Dubois AE, Hourihane JO. Food allergy QoL questionnaire', 'for children aged 0-12 years: content, construct, and cross-cultural validity. Clin Exp Allergy.', '2008;38(6):977-86.', 'DunnGalvin A, McMahon S, Ponsonby AL, Hsiao KC, Tang MLK, on behalf of the PPOIT study team. The', 'longitudinal impact of probiotic and peanut oral immunotherapy on health-related quality of life. Allergy.', '2017 Oct 20:1-9. [Epub ahead of print]']", "completion": ""}